Result of General Meeting

Renalytix PLC

22 April 2024

 

Renalytix plc

("Renalytix" or the "Company")

Result of General Meeting

LONDON and SALT LAKE CITY, 22 April 2024 - Renalytix plc (NASDAQ: RNLX) (LSE: RENX) announces that at the General Meeting ("GM") held earlier today all resolutions were passed. Further details of each of the resolutions are set out in Proxy Statement that contains the Notice of General Meeting, which was sent to shareholders on 3 April 2024.

The results of the GM are detailed below:

Resolution		Votes in favour	%		Votes against	%		Votes withheld
Resolution 1		50,091,780	98.77%		621,329	1.23%		120,431
Resolution 2		45,880,130	90.47%		4,832,979	9.53%		120,431
Resolution 3		50,072,092	98.74%		641,404	1.26%		120,044
Resolution 4		45,853,622	90.42%		4,859,914	9.58%		120,004

For further information, please contact:

Renalytix plc James McCullough, CEO	www.renalytix.com Via Walbrook PR
Stifel (Nominated Adviser to the Company) Nicholas Moore / Alex Price / Nick Harland / Samira Essebiya / Harry Billen	Tel: [phone]
Investec Bank plc Gary Clarence / Shalin Bhamra	Tel: [phone]
Walbrook PR Limited Paul McManus / Alice Woodings / Charlotte Edgar	Tel: [phone] or [e-mail] Mob: [phone]
CapComm Partners Peter DeNardo	Tel: [phone] or [e-mail]

About Renalytix

Renalytix (NASDAQ: RNLX) (LSE: RENX) is an in-vitro diagnostics and laboratory services company that is the global founder and leader in the new field of bioprognosis™ for kidney health. The leadership team, with a combined 200+ years of healthcare and in-vitro diagnostic experience, has designed its KidneyIntelX laboratory developed test to enable risk assessment for rapid progressive decline in kidney function in adult patients with T2D and early CKD (stages 1-3). We believe that by understanding how disease will progress, patients and providers can take action early to improve outcomes and reduce overall health system costs. For more information, visit www.renalytix.com.

 

END